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 Summary
  Primitive neuroectodermal tumors (PNET) belong to embryonal tumors. They often comprise 
the highly malignant and invasive neoplasms of childhood. The classification of PNET includes 
medulloblastoma, the most important tumor of posterior fossa and supratentorial primitive 
neuroepithelial tumor, known as S-PNET. These tumors have a tendency to disseminate throughout 
CSF and cause subarachnoid metastases, which is associated with low survival rate.
  We present epidemiologic, clinical and pathogenic aspects of these tumors groups. Computer 
tomography is the initial modality in diagnosis of PNET, but magnetic resonance imaging is of 
primary significance.
  The information about MR spectroscopy application in patients with neuroectodermal neoplasms 
is scarce. Only in a few articles, based on MRS in vitro and in vivo studies, there was elevated 
concentration of taurine in spectra of PNETs. Literature data suggest, that MR spectroscopy has 
relevant value in differential diagnosis and could be useful in assessment of prognosis. In our article 
we attempt to review the literature concerning neuroectodermal tumors and take ours clinical 
cases into account.
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Primitive neuroectodermal tumors (PNET) belong to the 
group of tumors of embryonal origin. They are childhood 
tumors with high grade IV histological malignancy, develop-
ing from undifferentiated or low-differentiated neuroepithe-
lial cells with multidirectional transformation potential [1,2].
Classification of these tumors is unequivocal. However, 
tumors with sub- and supratentorial location can be dis-
tinguished (Table 1). Medulloblastomas are predominant 
among subtentorial tumors). Supratentorial lesions (S-PNET 
– supratentorial PNET) include blastic forms of pineal body 
tumors, tumors of the cerebral hemispheres (with cortical 
or subcortical localization), as well as lesions of the thala-
mus and suprasellar ones [3,4].
The peak of PNET diagnoses falls between 4 and 8 years 







– nodular type with high neuronal diff erentiation
– gigantocellular type
Primitive neuroectodermal tumor (supratentorial)
– (Supratentorial S-PNET)
Atypical teratoid/rhabdoid tumor (AT/RT)
Table 1. Embryonal tumors according to Osborn AG et al. [6].
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rare and account only for 1–2% of all neoplasms [4]. Another 
peak of PNET diagnoses is observed between 20 and 24 
years of age, as ca. 30% of these tumors become manifest 
in adults [5]. Subtentorial PNET occurs in 75% of cases 
below 10 years of age, but it is diagnosed most frequently 
at the age of ca. 5 years [6], whereas S-PNET is most often 
observed in younger children – 50% of these tumors become 
manifest below 5 years of age, and ca. 10% in the first year 
of life, but the mean age of diagnosis is 35 months [5,6]. 
Supratentorial tumors account for 1% of all CNS neoplasias 
and 5.6% of all primitive neuroectodermal tumors of the 
CNS [6]. The dynamics of growth in childhood is the reason 
for high malignancy and rapid growth rate of these tumors. 
In imaging studies, they are visualized as large heteroge-
neous lesions, often causing hydrocephalus. They also tend 
to infiltrate the cerebrospinal meninges and spread through 
the cerebrospinal fluid [7]. Distant metastases, most fre-
quently to the bones, bone marrow, lymph nodes and liver 
are common [8].
Meduloblastoma, also referred to as PNET of the posterior 
cranial fossa (subtentorial PNET) belongs to the most fre-
quent embryonal tumors (70% of cases). It constitutes 40% 
of all posterior cranial fossa tumors and 15–20% of all pedi-
atric cerebral tumors [3,8]. It occurs in four forms: typi-
cal desmoplastic medulloblastoma, gigantocellular medul-
loblastoma, accounting for ca. 4% of cases, as a pigmented 
tumor type and a nodular type with highly differentiated 
neuronal structure, sometimes referred to as cerebellar 
neuroblastoma [6,8]. PNET is most often localized within 
the cerebellar vermis (ca 75% of cases), infiltrating the 
vault of the IV ventricle and the adjacent structure, which 
leads to rapid development of hydrocephalus. Usually the 
tumor is located in the medial line, filling the IV ventricle, 
but laterally located lesions spreading to the cerebellopon-
tine angle are also described [3,8]. Lateral location is char-
acteristic in older children and adults [6]. Laterally located 
lesions may cause connective tissue reaction, causing the 
growth of fibrous tissue in the vicinity of the tumor [5]. 
A
Figure 1.  Histologically confi rmed PNET in a 12-year-old child. Axial T1-weighted MR image (A). Axial T2-weighted MR image – high intensity 
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Meduloblastomas reach reletively big sizes, even up to 1–3 
cm [6].
The literature emphasizes genetic factors determining 
the development of PNET type neuroectodermal tumors 
[1]. The described cytogenetic changes include structural 
aberrations in chromosome 17q (short arm loss), balanced 
translocation, presence of the suppressor gene TP53 as well 
as the PAX gene [6]. Many recent reports indicate a cor-
relation between sporadic occurrence of medulloblastomas 
and a defect in the so-called Sonic Hedgehog (SHH) signal-
ing system. Mutations of PTCH1 gene (within chromosome 
9) and/or deletions of chromosome 9q elements associated 
with PTCH inactivation are observed in 30–40% of medul-
loblastoma. Additionally, mutations of the Suppressor of 
Fusem (SUFU) gene (10q24.3), which is a component of the 
SHH pathway, are also characteristic of this medulloblas-
toma variant and may have prognostic significance [1]. The 
presence of this tumor can be associated with such syn-
dromes as Gorlin, Li-Fraumeni, Turcot, Gardner, Bowden 
syndrom and ataxia-telangiectasia syndrome (Louis-Barr 
disease) [5,6].
PNET is usually a highly malignant and invasive tumor [6]. 
Its microscopic structure presents densely packed, hyper-
chromatic cells with pale cytoplasm, characterized by high 
nucleus to cytoplasm volume ratio, high mitotic index and 
neurono-neuroblastic differentiation manifested by forma-
tion of Homer-Wright rosettes [9,10].
As far as imaging studies are concerned, CT visualizes it as 
a hyperdense, homogeneous tumor, usually oval in shape 
and well-delineated. In 20% of cases, it contains calcifica-
tions, in 40–50% – cystic and necrotic lesions. Hemorrhagic 
lesions, iron and melanin deposits as well as fibrous areas 
can be seen. After contrast administration, the tumor 
undergoes considerable, relatively homogeneous enhance-
ment, with no enhancement in the areas corresponding to 
cysts and necrosis [3–6].
In MR, in T1-weighted images, PNET is a tumor hypoin-
tense in comparison with the gray matter, in T2-weight-
ed images iso- or hyperintense (Figure 1A,B). The FLAIR 
sequence is also useful in MR imaging, as it allows to visu-
alize the tumor well on the background of cerebrospinal 
fluid in the IV ventricle (Figure 1C). After contrast admin-
istration, PNET is significantly, often inhomogeneously 
enhanced (Figure 1D). Wilke et al. [11] believe that the 
decrease of ADC value in diffusion studies reflects small-
cell texture of the tumors and is charActeristic of PNET, 
whereas Schneider et al. [12] suggest that combined DWI 
and MRS techniques allows to differentiate posterior cra-
nial fossa tumors in children – among others, PNET, epen-
dymoma, pilocytic astrocytoma. Positron emission tomog-
raphy (PET) with the use of FDG, 11C-methionine and 11C-
choline can also be useful [13].
Differential diagnostics of subtentorial PNET folms 
should take into consideration astrocytomas – pilocytic 
A
Figure 2.  Inoperable pilocytic astrocytoma in a 26-year-old patient 
classifi ed to radiotherapy. Hyperintense signal tumor 
localized in the brainstem and cerebellar peduncles in axial 
T2-weighted image (A) and in axial FLAIR sequence (B). 
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(Figure 2A–C) and hairy cell astrocytoma, which is a cys-
tic tumor with nodular contrast enhancement [6]. In older 
children also ependymoma should be considered – an inho-
mogeneous tumor with calcifications and hemorrhagic 
areas (Figure 3A–D) [6]. Differential diagnostics also takes 
into account papilloma located in the IV ventricle, showing 
strong and homogeneous contrast enhancement with less 
significant mass effect [6]. Since atypical PNET forms occur 
particularly often in adults, PNET should always be con-
sidered in differential diagnostics of posterior cranial fossa 
tumors [14].
If a PNET is suspected, contrast administration is necessary 
to detect metastatic foci in the spinal canal as a result of 
spread through CSF [2,3,6,15]. Metastases in the subarach-
noid space are found in 50% of cases, therefore if there is a 
suspicion of PNET it is recommended to extend the diag-
nostics and to examine the spinal canal as well [3,15].
Clinical symptoms are early and may include ataxia, dizzi-
ness, increased intracranial pressure, cranial nerve palsy. 
On physical examination, papilloedema on the eye fundus, 
nystagmus, dysdiachokinesia or hypotonia can be observed. 
In case of spinal PNET location, the patient can experience 
nuchal pain, pain and weakness of the lower extremities, 
impairment of intestinal and cystic function, leading to uri-
nary incontinence [6,8].
The aim of surgical treatment of PNET is to remove the 
tumor and to restore normal CSF flow. The effectiveness of 
chemo- and radiotherapy, also in younger children, has been 
demonstrated. However, radiotherapy can be used only in 
children above 3 years of age [16,17]. The factors deter-
mining effectiveness of the therapy include: age (below or 
above 3 years of age), tumor size (smaller or larger than 1.5 
cm2), brain stem involvement and/or the presence of metas-
tases in imaging studies or CSF cytology [8].
The 5-year survival rate amounts to 80–85% [6]. Such a 
low index is due to the fact that PNET shows a tendency to 
relapse, even a case of late relapse 21 years after resection 
of the primary tumor has been described [18].
MR spectroscopy
There are only a few reports concerning MR spectroscopy 
performed in PNET patients. These tumors, just like other 
CNS neoplasms, are characterized in 1H MRS spectra by 
A D
C
B Figure 3.  Histologically proven ependymoma of the IV ventricle in a 
71-year-old patient. Axial T1-weighted image before (A) 
and after administration of gadolinium – axial (B) and 
coronal plane (C). Hypointense signal tumor with strong, 
irregular enhancement. Heterogeneous signal intensity of 
the tumor in T2-weighted image (D).
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reduced NAA content and elevated choline [5]. Such chang-
es of metabolite content in case of PNET patients were 
observed, among others, by Chawla et al. and Tugnoli et 
al. [15,19]. High choline content is associeted with tumor 
structure with densely packed cells and increased mem-
branous structure transformation. Majos et al. [20] state 
that a characteristic feature of PNET in MRS spectra is 
also the lack of lipid bands, which distinguishes PNET 
among other highly malignant tumors such as glioblasto-
mas.
Additional information concerning the metabolic profile 
of PNET were obtained from in vitro studies using high 
resolution MR spectroscopy. Tugnoli et al. [19] detected 
increased concentrations of myoinositol, taurine and phos-
phorylethanolamine – a component of choline band, where-
as Sutton et al. [21] observed in 9 PNET cases the presence 
of glycine, taurine and inositol bands and considerable 
increase of choline content (Cho/NAA), with less marked 
increase of glutamate/glutamine proportion. A significant 
increase of taurine content in such tumors was also demon-
strated by Kinoshita et al. [22].
The presence of a taurine band in a medulloblastoma patient 
in 1H MRS performed in vivo was first described by Wilke 
et al. [11]. Majos et al. [20] demonstrated increased taurine 
levels in adult patients with PNET. The presence of this 
compound in 3 PNET patients was also observed by Chawla 
et al. [15], and the presence of a taurin band in PNET spec-
tra are confirmed by observations of Japanese authors [23].
Taurine, 2-aminoethanosulfonic acid, is an organic com-
pound commonly regarded as an amino acid, although it 
does not have a carboxyl group. It is involved in metabo-
lism of bile acids in the liver and in creatine transport in 
skeletal muscles. It is also present in the CNS, where it is 
involved in osmotic processes and probably plays a role 
of a neurotransmitter inhibiting the dopaminergic system 
[24]. In normal CNS, taurine is present in the cerebellum, 
Purkinje cell bodies, short neuronal projections, Golgi axial 
fibers, cerebellar cortex basket cell axon terminals and 
neuroglia processes [25–27]. Crabai et al. found high tau-
rine levels in normal pineal body, pituitary and retina [28]. 
Flint et al. [29] demonstrated considerable concentrations 
of taurine in the developing cerebellum and the neocortex. 
Age-related changes of taurine content in different periods 
of brain development were described by Pouwels et al. [30] 
and Kreis et al. [31].
Assessment of taurine content in in vivo MRS studies is dif-
ficult because of its low content in the brain and partial 
overlap between the taurine band and the signals of other 
compounds, such as scillo-inositol or glucose. However, 
more advanced techniques of MR spectroscopy allow even 
quantitative measurements of taurine content [30,31].
The largest clinical study concerning this problem included 
13 patients [32]. In all the cases, increased taurine content 
was found in in vivo MRS, which was also confirmed in 
high-resolution spectroscopy. The authors of the report sug-
gest that high content of this compound is highly pathogno-
monic for PNET type tumors.
Both the presence of taurine band and other spectroscopic 
features such as significant depletion of NAA, markedly 
increased concentrtion of choline compounds and the lack 
of lipid bands make up the spectroscopy standard for PNET 
(Figure 4). Thus, MR spectroscopy contributes some impor-
tant elements to differential diagnostics when PNET is 
suspected, which is confirmed by comparative analysis of 
different subtentorial tumor spectra performed by Majos 
et al. [20] (Figure 5). On interpretation of the spectra, how-
ever, it should be remembered that taurine level can also 
be increased in other embryonal tumors, e.g. of the pineal 
body, or in highly malignant astrocytomas [32,33].
Spectroscopic data can also provide a clue for consideration 
of the origins of neuroectodermal tumors. Such conclu-
sions can be drawn from the study by Florian et al. [34], 
who found on the basis of in vitro spectroscopic studies 
that NAA expression in PNET cells correlates negatively 
with their neuronal differentiation, which may indicate 
that these cells originate from precursor cells with type 2 
oligodendrocytic phenotype. On the other hand, increased 
level of taurine, a compound present in high concentration 
in immature brain, observed in PNET spectra, undoubt-
edly confirms that the tumor originates from primitive and 
undifferentiated neural cells [31].
Figure 4.  MR spectroscopy shows decreased N-acetylaspartate level, 
increased concentration of choline and a peak of taurine in 
histologically proven PNET in a 12-year-old child.
Figure 5.  Spectrum of pilocytic astrocytoma during radiotherapy 
shows slight decrease in N-acetylaspartate level and 
increased concentration of choline compounds. Increased 
glutamine/glutamate ratio and marked elevation of lactates 
as a result of radiotherapy.
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Spectroscopy seems also to be potentially useful in prog-
nostic assessment. Peet AC et al. [35] demonstrated, that 
MRS metabolic profiles allow to differentiate PNET forms 
associated with high risk of metastases from limited, 
well-delineated forms. Dembowska-Bagińska et al. [36] 
believe that metabolite levels assessed in MR spectros-
copy correlate significantly with the course of thr dis-
ease and the instituted chemotherapy, whereas Peeling et 
al. [33] suggest that taurine content may correlate with 
tumor malignancy, and quantitative measurements of 
taurine in MR spectroscopy in vivo may have prognostic 
value.
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